<DOC>
	<DOC>NCT00486785</DOC>
	<brief_summary>Primary Objective: - To assess the sexual function improvement from baseline to the end of treatment (Week 24 or premature withdrawal (PW)) with XATRAL 10mg OD. Secondary Objective: - To evaluate the association between Lower Urinary Tract Symptoms (LUTS) severity and sexual disorders, - To compare the improvement in sexual function, urinary symptoms and Quality of Life among the different regions, - To correlate MSHQ (Male Sexual Health Questionnaire) and IIEF-5 (the 5-Item version of the International Index of Erectile Function), - To assess the onset of action of XATRAL 10mg OD, - To assess the peak flow rate improvement (Qmax), - To assess the safety and the tolerability of XATRAL 10mg OD.</brief_summary>
	<brief_title>SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Patients suffering from moderate to severe lower urinary tract symptoms (LUTS), suggestive of symptomatic Benign Prostatic Hyperplasia (BPH), Patients with an IPSS total score ≥ 8, Patients sexually active Known history of hepatic or severe renal insufficiency, unstable angina pectoris, concomitant threateninglife condition. Previous prostate surgery, minimally invasive procedure within 6 months prior to inclusion. Planned prostate biopsy, prostate surgery or minimally invasive procedure during the whole study period. Active urinary tract infection or prostatitis, neuropathic bladder, a diagnosed prostate cancer. Patients having received 5αreductase inhibitors or LUTS related phytotherapy within 6 months prior to inclusion, or α1blockers within 30 days prior to inclusion. Patients receiving any treatment for erectile dysfunction (i.e. phosphodiesterase5 inhibitors) at inclusion. History of postural hypotension or syncope. Known hypersensitivity to alfuzosin. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>